Oura to acquire AI-native primary care startup Counsel Health

Open the source listing →

Oura announced on Tuesday that it agreed to acquire Counsel Health, an artificial intelligence primary care startup, in a transaction valued at $625 million. According to TechCrunch's report, the acquisition follows Oura's decision to postpone its planned initial public offering of up to $2.2 billion indefinitely because of market uncertainty. The transaction pairs the hardware ring maker with a dedicated medical software provider.

This report details the corporate acquisition, the operational integration between wearable sensors and clinical teams, and Oura's financial metrics. The analysis serves hardware owners, digital healthcare operators, and industry analysts tracking wearable diagnostics and clinical telemedicine services. It breaks down the commercial terms, service capabilities, competitive dynamics, and regulatory timeline guiding the union.

01Primary care platform acquisition and integration

Counsel Health operates an artificial intelligence platform designed to combine chat-based clinical evaluations with direct consultations from licensed physicians. The service initially launched an integration within the official Oura mobile application in June. That initial deployment enabled ring wearers to query medical algorithms directly while maintaining access to human doctors.

The two organizations are now expanding beyond their preliminary interface to create comprehensive clinical systems across preventative wellness, acute care, chronic illness maintenance, and specialty medicine. By integrating diagnostic algorithms directly with wearable tracking, the combined system seeks to transition passive sensor collection into active medical consultations.

Counsel Health secured a $25 million Series A investment round one year ago under the lead participation of Andreessen Horowitz and GV. Industry research firm PitchBook estimates that Counsel Health accumulated approximately $36 million in aggregate capital prior to the buyout. Oura is deploying that acquired software stack across its broader commercial footprint.

02In-app medical chat and physician access

Within the mobile interface, members interact directly with Counsel Health's clinical artificial intelligence to receive personalized guidance based on their ongoing biometric trends. When algorithmic evaluation requires human oversight, patients can initiate secure text conversations with licensed medical doctors without leaving the application. This dual structure prevents unmonitored automated prescriptions while streamlining patient access.

The service coordinates medical workflows spanning quick health inquiries, prescription issuance, diagnostic laboratory interpretations, and medical specialist referrals. Oura chief executive officer Tom Hale explained in a press release that members can use Counsel to take direct action on health data across those daily requirements. That framework links physiological baseline shifts directly to licensed clinical interventions.

03Hardware ring rivals and clinical strategy

Oura has maintained a leading position across the consumer smart ring category for several years through consecutive hardware releases. Rising competition from emerging wearable manufacturers such as RingConn and Ultrahuman has introduced fresh pressure to differentiate beyond physical sensor hardware. Investing $625 million into direct medical care allows Oura to expand into professional diagnostic services.

The strategic shift comes after Oura indefinitely postponed its planned public listing of up to $2.2 billion, citing uncertainty across public financial markets. Instead of seeking liquidity through a public offering, the company chose to deploy capital toward vertical healthcare integration. Expanding clinical utility offers a defense against low-cost ring rivals entering global consumer markets.

04Team transition and enterprise health expansion

Under the finalized transaction terms, Counsel Health chief executive officer Muthu Alagappan will transition to Oura as chief clinical AI officer. Bloomberg reports that Alagappan will bring Counsel Health's entire team of 70 employees into Oura's organizational structure. This personnel transfer concentrates clinical artificial intelligence engineers and healthcare operators under Oura's product leadership.

Alagappan stated in the announcement release that Counsel Health developed its medical artificial intelligence around trust, safety, and responsibility while keeping licensed physicians central to clinical choices. He noted that Oura's objective context, trended biometrics, and member engagement enable clinicians to provide informed care. He confirmed that both leadership groups negotiated the transaction over several months.

Following the acquisition, Counsel Health will maintain and expand relationships with current and prospective enterprise clients. Oura plans to distribute Counsel Health's AI-native care delivery model to broader corporate populations beyond existing ring wearers. This enterprise strategy allows commercial organizations and healthcare partners to deploy physician-backed medical artificial intelligence at scale.

05Closing timeline and fiscal revenue expansion

The acquisition agreement between Oura and Counsel Health remains subject to regulatory review and standard closing conditions. Both corporate entities anticipate that the formal transaction will close before the end of 2027. Counsel Health will continue operating its clinical features and enterprise contracts while closing procedures proceed.

Alongside the transaction announcement, Oura disclosed that its quarterly revenue expanded 153% year-over-year to $533 million for the quarter ended September 30. For fiscal year 2026, the company generated approximately $1.75 billion in total revenue, representing a 92% year-over-year increase. Oura previously secured an $11 billion corporate valuation after closing a $900 million late-stage venture financing round in October 2025.